Psychedelic Renaissance: Clinical Health Justice, Patient Safety, and Equity Need to Be Put First
Jacques Ambrose, Jeffrey S Zabinski
Psychiatric News February 16, 2023 DOI: 10.1176/appi.pn.2023.03.3.43 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Key points | The text frames the coming FDA review of phase 3 MDMA-assisted psychotherapy data for PTSD as a moment for experts to weigh ethical considerations, appropriate use, and access, while noting sustained and growing interest in psychedelics and their long history of Indigenous ceremonial use. |
Abstract
With the impending FDA review of the phase 3 data for MDMA-assisted psychotherapy for PTSD, experts reflect on ethical considerations, appropriate use, and access. The groundswell of interest in psychedelics in psychiatry, medicine broadly, and in popular culture continues without a peak in sight. Though the term “psychedelic” was coined in the 20th century, these compounds have an extensive history of use by Indigenous peoples, often related to traditional or ceremonial use.